Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE2 | O96020 | 6/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 6/20 | 0.49 |
| ▸ | CDK2 | P24941 | 6/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | CDK4 | P11802 | 4/20 | 0.40 |
| ▸ | CCND1 | P24385 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30297757 | 1.00 | CCNE2 (0.49) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| SCHEMBL8073916 | 0.86 | POLB (0.43) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| SCHEMBL9998118 | 0.84 | CDK2 (0.57) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| SCHEMBL30540343 | 0.84 | CDK2 (0.57) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| SCHEMBL4426259 | 0.83 | CCNE2 (0.47) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| SCHEMBL7436724 | 0.83 | CDK2 (0.41) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| SCHEMBL27138975 | 0.83 | LMNA (0.49) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| SCHEMBL14190005 | 0.83 | CCNE2 (0.50) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| SCHEMBL6372133 | 0.79 | CCNE2 (0.39) | CCNE2CCNE1CDK2CCNA2CCNA1 | |
| SCHEMBL8073927 | 0.79 | CDK2 (0.41) | CCNE2CCNE1CDK2CCNA2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606255-B1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2009-11-11 | — | — | EP | disclosed |
| EP-2098508-A1 | Cyclic derivatives as modulators of chemokine receptor activity | Bristol-Myers Squibb Company (US) | 2009-09-09 | — | — | EP | disclosed |
| US-20080114052-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-7338947-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB CO. (US) | 2008-03-04 | — | — | US | disclosed |
| WO-2007042669-A2 | DERIVATIVES OF 4-AMINO-QUINAZOLINE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFIS-AVENTIS (FR) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007042669-A2 | DERIVATIVES OF 4-AMINO-QUINAZOLINE, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS | SANOFIS-AVENTIS (FR) | 2007-04-19 | — | — | WO | disclosed |
| US-7183270-B2 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-27 | — | — | US | disclosed |
| US-20070032541-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CHERNEY ROBERT J | 2007-02-08 | — | — | US | disclosed |
| EP-1606255-A4 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL MYERS SQUIBB CO (US) | 2007-02-07 | — | — | EP | disclosed |
| EP-1606255-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | Bristol-Myers Squibb Company (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2004-09-23 | — | — | US | disclosed |
| WO-2004071460-A2 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114052-A1 | CYCLIC DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | CCL11, CCL2, CCR1 | CCNE2 3521/4885CCNE1 2636/4885CDK2 3132/4885 |
| US-20040186140-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCL2 | CCNE2 3629/4885CCNE1 2444/4885CDK2 3240/4885 |
| US-20070032541-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | CCNE2 3521/4885CCNE1 2636/4885CDK2 3132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.